rBS-WC(O139)霍乱疫苗的小鼠免疫试验

1992年起在印度和孟加拉国相继发生的O139霍乱,目前已迅速传播到其周边国家,对我国亦已构成严重威胁。当前全世界预防霍乱的工作更加复杂,除了要针对O1群霍乱弧菌研制保护期长、保护效率高的疫苗外,还要对这一新发现的时隐时现的烈性腹泻病原菌快速作出反应,及时分析其保护性抗原,构建有效疫苗,以控制疫情发展。 O139霍乱弧菌与O1群霍乱弧菌有很大不同,特别在菌体抗原方面存在显著差异。O1群菌感染的患者康复后对同群菌的冉感染有免疫保护作用,而对O139群菌的感染则无此保护作     

霍乱cT-B和LPs-o双价抗原工程菌苗株的构建

作者将霍乱弧菌O抗原及毒素B亚单位基因片段,经DNA体外重组技术,得到了能表达双价抗原的工程菌株1046(pMG305)。经GM1-ELISA分析表明该菌株能够表达特异的霍乱CT-B抗原,且能分泌到胞外,通过菌体凝集,全细胞O抗原酶联分析和血凝抑制试验表明在1046(pMG305)菌体表面表达了霍乱的O抗原,它的脂多糖O抗原通过SDS-PAGE电泳分析,显示它表达了霍乱LPS的特征区带。小鼠腹腔免疫后用霍乱弧菌毒株攻击表明,有良好的保护作用,因此1046(pMG305)可望成为霍乱活疫苗的候选株。     

霍乱cT-B和LPs-o双价抗原工程菌苗株的构建

作者将霍乱弧菌O抗原及毒紊B亚单位基因片段,经DNA体外重组技术,得到了能表达双价抗原的工程菌株1046(pMG305)。经GMl一ELlsA分析表明该菌株能够表达特异的霍乱cT—B抗原,且能分泌到胞外,通过菌体凝集,全细胞O抗原酶联分析和血凝抑制试验表明在1046(pMG305)菌体表面表达了霍乱的0抗原,它的脂多糖O抗原通过sDS-PAGE电泳分析．显示它表达了霍乱LPs的特征区带。小鼠腹腔免疫后用霍乱弧菌毒株攻击表明．有良好的保护作用．因此1046(pMG30s)可望成为霍乱活疫苗的候选株。     

霍乱O139血清群多糖结合疫苗的生物合成研究

目的:霍乱是由霍乱弧菌引起的一种烈性传染病,其防治已成为一个全球性的公共卫生问题。其中1992年出现的O139血清群是除O1外另一种病原体,发病数日益增多。因此,有必要寻找一种安全有效适用于各种人群的疫苗。方法:敲除霍乱弧菌O139血清群93-3株脂多糖合成途径中O抗原连接酶基因waa L,在周间质产生游离的多糖,之后转入包含来自脑膜炎奈瑟球菌的糖基转移酶和霍乱毒素B亚单位(CTB)编码序列的共表达载体,经IPTG诱导后制备全菌蛋白样品,利用抗His抗体检测糖蛋白的表达,利用Ni柱和离子交换柱对糖蛋白进行纯化,并对其进行糖定量和蛋白定量。结果:以未糖基化、相对分子质量约为14×103的底物蛋白CTB为对照,当共表达CTB和糖基转移酶Pgl L时,通过Western印迹可检测到相对分子质量约为20×103的糖基化蛋白,经Ni柱及阳离子交换柱纯化,得到纯度较高的O139群霍乱O抗原多糖结合蛋白,其纯度约为84.2%,并计算得其糖-蛋白比为0.103∶1。结论:通过生物法合成了一种霍乱O139血清群的多糖结合疫苗,为后续进行动物评价打下了基础。     

霍乱O139型菌苗的试制

对来自孟加拉、泰国、印度、中国四地区Ｏ１３９型霍乱菌株进行了毒力、免疫原性、免疫力与相互交叉保护力试验,结果显示不同地区分离的Ｏ１３９型霍乱弧菌其所试特性相互间无差异。用中国（９３－３）株试制的菌体菌苗,其抗原性、毒性、免疫力安全性等经检定符合霍乱菌苗规程要求。鉴于Ｏ１３９型霍乱弧菌存在荚膜的特性,而现有的几种荚膜多糖菌苗都显示有明显的保护作用,因而,使用Ｏ１３９型菌苗有可能在一定程度上达到控制Ｏ１３９型霍乱流行的目的。     

霍乱弧菌O139群菌苗研究进展

本文综述了目前研制出的Ｏ１３９群口服菌苗,包括灭活菌苗,基因工程减毒活菌苗和基因工程加法菌苗;阐述了有关Ｏ１３９群菌苗的基础研究,包括Ｏ１群和Ｏ１３９群的分子遗传学关系。Ｏ１３９群感染的免疫机制和产生的保护机制。     

非O1群O139群霍乱的研究进展

１９９２年９月首次分离到Ｏ１３９群霍乱菌株以来,亚洲多个国家和地区发生了Ｏ１３９群霍乱弧菌所致霍乱的流行,本文对Ｏ１３９群霍乱的微生物学、免疫学、分子生物学、诊断方法及流行病学等方面的研究作一简述。     

1985年孟加拉国口服霍乱菌苗现场考核

<正> 由于常规霍乱菌苗保护力低,人们注意力已转向了更能有效刺激肠道免疫的口服菌苗。本文,我们评价了口服B亚单位-全菌体死菌苗(BS-WC),与全菌体死菌苗(WC)的保护效果(PE)。     

O2血清型肺炎克雷伯氏菌多糖结合疫苗的生物合成

本研究旨在利用微生物体内合成肺炎克雷伯氏菌 (Klebsiella pneumoniae,Kp) 多糖结合疫苗并研究其保护效果。通过敲除Kp O抗原连接酶基因waaL阻断其LPS合成,再向缺失株中导入糖基工程载体,使细菌能够在体内合成糖蛋白,并将该糖蛋白免疫小鼠后评价其保护效果。结果表明,在构建的 Kp waaL缺失株中导入糖基工程载体后,底物蛋白重组霍乱毒素B亚单位rCTB (Recombinant cholera toxin B subunit) 能够被O糖化,从而得到糖蛋白;动物实验结果显示该疫苗能刺激小鼠产生较高的抗体效价,试验组小鼠攻毒后一周存活率可达75%。这种生物合成方法制备的多糖结合疫苗有望成为针对肺炎克雷伯氏菌的新型候选疫苗。     

用霍乱鞭毛一类毒素联合疫苗免疫成年家兔产生较强的抗霍乱保护作用

<正> 霍乱类毒素不能产生理想的免疫力。新近Svennerholm等(1976)和Peterson)1979)报导,类毒素和菌体抗原同时免疫可提供协同保护作用,认为这是由于类毒素和菌体抗原的免疫原性在二个不同阶段阻断发病过程。Yancey(1979)以带鞘鞭毛粗制品免疫的家兔在受霍乱弧菌攻击后不产生迴肠结扎环的肠液储留,表明负责这种保护作用的主要免疫原与鞭毛有关。虽然,究竟是     

冻干口服霍乱rBS—WC菌苗安全及保护效果评价的小鼠模型探讨

本文仿照人口服免疫程序用小鼠为模型对冻干口服霍乱ｒＢＳ－ＷＣ菌苗制品进行了安全及保护率评价。给ＫＭ小鼠口服三种不同剂量的ｒＢＳ－ＷＣ菌苗后,无发病,无体重减轻,无死亡现象,表明该菌苗安全,无毒副作用。免疫组与安慰剂组小鼠用肠结扎攻毒试验评价保护效果,两组小鼠用吴江－２及滨－４３活菌攻击后,免疫组显示良好保护作用（Ｐ＜０．０５）。此法可以用于口服型ｒＢＳ－ＷＣ菌苗的评价,但也存在需要动物数较多,个体间差异较大,手术较麻烦的问题。     

Peptides mimicking Vibrio cholerae O139 capsular polysaccharide elicit protective antibody response

Vibrio cholerae is the etiological agent of cholera. V. cholerae serogroup O1 had been, until 1992, the only serogroup responsible for large epidemics and pandemics of cholera. In 1992, a new serotype of V. cholerae emerged in South-East Asia that caused a massive outbreak of cholera in India and neighboring countries. The new serotype was named V. cholerae O139. The main differences between V. cholerae O139 and O1 are that the former possesses a capsular polysaccharide and different lipopolysaccharide. Capsular polysaccharides are, in general, T-independent antigens giving rise to poor immune responses lacking immunological memory. In order to overcome this, monoclonal antibodies against the capsular polysaccharide of V. cholerae O139 were used to screen different phage-displayed random peptide libraries. Eight different phage clones were selected and characterized using enzyme immunoassay with the monoclonal antibodies, and then tested for specificity by competition with V. cholerae O139 capsular polysaccharide. Selected peptides were sequenced, synthesized and conjugated to bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH). The conjugated peptides were used to immunize mice. It is evident that the anti-peptide mouse antibodies bind to the V. cholerae O139 capsular polysaccharide. In addition, the anti-peptide antibodies are protective in a suckling mouse model. The protective efficacy is both specific and dose-dependent. A PCT (PCT/IT2003/000489) with the publication number WO 2004/056851 has been filed for the sequences of the eight peptides.     

Seasonal cholera caused by Vibrio cholerae serogroups O1 and O139 in the coastal aquatic environment of Bangladesh

Since Vibrio cholerae O139 first appeared in 1992, both O1 El Tor and O139 have been recognized as the epidemic serogroups, although their geographic distribution, endemicity, and reservoir are not fully understood. To address this lack of information, a study of the epidemiology and ecology of V. cholerae O1 and O139 was carried out in two coastal areas, Bakerganj and Mathbaria, Bangladesh, where cholera occurs seasonally. The results of a biweekly clinical study (January 2004 to May 2005), employing culture methods, and of an ecological study (monthly in Bakerganj and biweekly in Mathbaria from March 2004 to May 2005), employing direct and enrichment culture, colony blot hybridization, and direct fluorescent-antibody methods, showed that cholera is endemic in both Bakerganj and Mathbaria and that V. cholerae O1, O139, and non-O1/non-O139 are autochthonous to the aquatic environment. Although V. cholerae O1 and O139 were isolated from both areas, most noteworthy was the isolation of V. cholerae O139 in March, July, and September 2004 in Mathbaria, where seasonal cholera was clinically linked only to V. cholerae O1. In Mathbaria, V. cholerae O139 emerged as the sole cause of a significant outbreak of cholera in March 2005. V. cholerae O1 reemerged clinically in April 2005 and established dominance over V. cholerae O139, continuing to cause cholera in Mathbaria. In conclusion, the epidemic potential and coastal aquatic reservoir for V. cholerae O139 have been demonstrated. Based on the results of this study, the coastal ecosystem of the Bay of Bengal is concluded to be a significant reservoir for the epidemic serogroups of V. cholerae.     

A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae O139.

Vibrio cholerae O139 is the first non-O1 serogroup of V. cholerae to give rise to epidemic cholera. Apparently, this new serogroup arose from an El Tor O1 strain of V cholerae, but V. cholerae O139 is distinguishable from V. cholerae El Tor O1 by virtue of its novel antigenic structure and also its characteristic pattern of resistances to the antibiotics sulfamethoxazole, trimethoprim, streptomycin, and furazolidone. We found that the first three of these antibiotic resistances are carried on an approximately 62-kb self-transmissible, chromosomally integrating genetic element which we have termed the SXT element. This novel conjugative transposon-like element could be conjugally transferred from V. cholerae O139 to V cholerae O1 and Escherichia coli strains, where it integrated into the recipient chromosomes in a site-specific manner independent of recA. To study the potential virulence properties of the SXT element as well as to improve upon the live attenuated O139 vaccine strain Bengal-2, a large internal deletion in the SXT element was crossed on to the Bengal-2 chromosome. The resulting strain, Bengal-2.SXT(s), is sensitive to sulfamethoxazole and trimethoprim and colonizes the intestines of suckling mice as well as wild-type strains do, suggesting that the SXT element does not encode a colonization factor. Derivatives of Bengal-2.SXT(s) are predicted to be safe, antibiotic-sensitive, live attenuated vaccines for cholera due to the O139 serogroup.     

Strains of Vibrio cholerae serogroups O1 and O139 that produce the basic protective antigens

To find out stable and effective producers of major protective antigens intended for use as components of cholera chemical vaccine against V. cholerae strains of serogroups O and O139, the comparative analysis of the production of cholera toxin, toxin-coregulated pili (TCP), antigens O1 and O139, polysaccharide capsule and outer membrane protein OmpU in different V. cholerae strains groups O1 and O139 has been made. V. cholerae strain KM68, serogroup O1, has been found capable of the production of antigen O1, serovar Ogawa, protein OmpU at a sufficiently high level and the hyperproduction of cholera toxin and TCP, and thus suitable for use in the manufacture of cholera bivalent vaccine as the source of these antigens. Specially selected alysogenic noncapsular strain KM137 of serogroup O139, characterized by a high and stable level of the biosynthesis of this somatic antigen when grown in both laboratory and production conditions, may serve as the produces of antigen O139.     

Comparative evaluation of activity of antibacterial agents in vitro and their efficacy in experimental cholera due to strains of Vibrio cholerae O1 and O139 serogroups in albino mice]

Activity of 16 antibacterial agents against human isolates of Vibrio cholerae O1 and O139 serogroups (P-5879, 4990, 143/23, and MO-45, P- 16065 respectively) was studied in vitro. The efficacy of the agents was studied in a model of generalized cholera in albino mice. Susceptibility of Vibrio cholerae P-5879 (used as the control) in the in vitro experiments with respect to the antibacterial agents correlated with their in vivo efficacy. The strains of Vibrio cholerae O1 and O139 serogroups isolated within the recent years had transmissive markers of resistance to streptomycin, trimethoprime/sulfamethoxazole, tetracycline, chloramphenicol and not transmitted by conjugation markers of resistance to rifampicin, furazolidone, nalidixic acid. The specific feature of the experimental infection due to such strains was the failure not only of the antibacterials of the resistance spectrum of the pathogen but also of the antibiotics showing in vitro susceptibility (betalactams, fluoroquinolones) that required additional bacteriological control on the 2nd or 3rd day of the etiotropic therapy for early replacement of the antibacterial agent.     

O1群和O139群霍乱弧菌主要抗原研究进展

霍乱弧菌是引起人和动物烈性肠道传染病霍乱的病原体。在霍乱弧菌的200多个血清群中,只有O1群和O139群霍乱弧菌能引起霍乱。快速准确检测O1群和O139群霍乱弧菌是霍乱防治的关键。表面抗原在O1群和O139群霍乱弧菌检测中发挥着重要作用。简要综述了O1群和O139群霍乱弧菌的脂多糖、霍乱肠毒素、外膜蛋白W、毒素共调菌毛和甘露糖敏感血凝素等5种主要抗原的研究进展。     

Method of DNA extraction and application of multiplex polymerase chain reaction to detect toxigenic Vibrio cholerae O1 and O139 from aquatic ecosystems

Vibrio cholerae is a free-living bacterium found in water and in association with plankton. V. cholerae non-O1/non-O139 strains are frequently isolated from aquatic ecosystems worldwide. Less frequently isolated are V. cholerae O1 and V. cholerae O139, the aetiological agents of cholera. These strains have two main virulence-associated factors, cholera toxin (CT) and toxin co-regulated pilus (TCP). By extracting total DNA from aquatic samples, the presence of pathogenic strains can be determined quickly and used to improve a microbiological risk assessment for cholera in coastal areas. Some methods suggested for DNA extraction from water samples are not applicable to all water types. We describe here a method for DNA extraction from coastal water and a multiplex polymerase chain reaction (PCR) for O1 and O139 serogroups. DNA extraction was successfully accomplished from 117 sea water samples collected from coastal areas of Perú, Brazil and the USA. DNA concentration in all samples varied from 20 ng to 480 micro g micro l-1. The sensitivity of the DNA extraction method was 100 V. cholerae cells in 250 ml of water. The specificity of multiplex O1/O139 PCR was investigated by analysing 120 strains of V. cholerae, Vibrio and other Bacteria species. All V. cholerae O1 and O139 tested were positive. For cholera surveillance of aquatic environments and ballast water, total DNA extraction, followed by V. cholerae PCR, and O1/O139 serogroup and tcpA/ctxA genes by multiplex PCR offers an efficient system, permitting risk analysis for cholera in coastal areas.     

Safety of the Recombinant Cholera Toxin B Subunit, Killed Whole-Cell (rBS-WC) Oral Cholera Vaccine in Pregnancy

Introduction

Mass vaccinations are a main strategy in the deployment of oral cholera vaccines. Campaigns avoid giving vaccine to pregnant women because of the absence of safety data of the killed whole-cell oral cholera (rBS-WC) vaccine. Balancing this concern is the known higher risk of cholera and of complications of pregnancy should cholera occur in these women, as well as the lack of expected adverse events from a killed oral bacterial vaccine.

Methodology/Principal Findings

From January to February 2009, a mass rBS-WC vaccination campaign of persons over two years of age was conducted in an urban and a rural area (population 51,151) in Zanzibar. Pregnant women were advised not to participate in the campaign. More than nine months after the last dose of the vaccine was administered, we visited all women between 15 and 50 years of age living in the study area. The outcome of pregnancies that were inadvertently exposed to at least one oral cholera vaccine dose and those that were not exposed was evaluated. 13,736 (94%) of the target women in the study site were interviewed. 1,151 (79%) of the 1,453 deliveries in 2009 occurred during the period when foetal exposure to the vaccine could have occurred. 955 (83%) out of these 1,151 mothers had not been vaccinated; the remaining 196 (17%) mothers had received at least one dose of the oral cholera vaccine. There were no statistically significant differences in the odds ratios for birth outcomes among the exposed and unexposed pregnancies.

Conclusions/Significance

We found no statistically significant evidence of a harmful effect of gestational exposure to the rBS-WC vaccine. These findings, along with the absence of a rational basis for expecting a risk from this killed oral bacterial vaccine, are reassuring but the study had insufficient power to detect infrequent events.

Trial Registration

ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00709410","term_id":"NCT00709410"}}NCT00709410     

Activity of 22 antibacterials against O1 and O139 serogroup Vibrio cholerae strains isolated from humans within 1927-2005 in various regions of the world]

Analysis of antibioticograms of 390 O1 and O139 serogroup Vibrio cholerae strains isolated from humans within 1927-2005 in various regions of the world showed that the strains of V. cholerae isolated within 1927-1966 were susceptible to 22 antibacterials, the strains isolated within 1938-1993 possessed 1-3 resistance markers and the strains isolated within 1994-2005 had 3-8 resistance markers including resistance to fluoroquinolones. All the strains of O139 serogroup V. cholerae isolated in 1993 and 1994 possessed 3 resistance markers. Studies on albino mice with generalized experimental cholera due to the V. cholerae eltor 1 strain (P-18826, 2005) isolated from a cholera patient, which was highly resistant to nalidixic acid, streptomycin, ampicillin and trimethoprim/sulfamethoxazole and showed cross resistance to fluoroquinolones (ciprofloxacin, ofloxacin, pefloxacin and norfloxacin) and moderate resistance to ceftriaxone and cefotaxime, revealed that the only efficient antibiotics were tetracyclines and aminoglycosides (except streptomycin). The investigation demonstrated an extension of the antibiotic resistance spectra of the epidemically significant strains of the cholera pathogen and the necessity of using antibacterial drugs in strict accordance with the antibioticograms in emergent prophylaxis and therapy of cholera and immediate replacement of the drug by a more active one.